Introduction: Neonatal Hypoxic-Ischemic Encephalopathy (nHIE) is a leading cause of infant mortality and long-term morbidity, with males experiencing higher mortality rates and poorer neurological ...

In the previous section, we analyzed paradigms that have evolved from experimental models. Clinical observations support the role of such pathophysiological mechanisms. As a consequence of the ...

Recognizing changes in the power of the very low-frequency component of the NIRS signal could help elucidate the role of the third intrinsic mechanism in the pathophysiology of neonatal AKI ... and ...

The role of glycolysis in the pathophysiology of IS remains a subject of ongoing debate. This review aims to comprehensively examine recent research on glycolysis and IS, exploring its involvement in ...

Zoe Van Schyndel is a writer and lecturer with 33+ years of experience in finance and investing. She previously worked as a branch chief with the SEC. Dr. JeFreda R. Brown is a financial ...

HOUSTON--(BUSINESS WIRE)--Hamershlag Private Capital Management Limited (HPCM), a leading health technology investment firm, has announced a significant venture investment in Patho Care ...

Sovateltide is under clinical development by Pharmazz and currently in Phase I for Hypoxic-Ischemic Encephalopathy. According to GlobalData, Phase I drugs for Hypoxic-Ischemic Encephalopathy does not ...